Abstract
Typical antipsychotic agents are commonly associated with hyperprolactinemia, which, in turn, leads to sexual dysfunction. The mechanism of action underlying this clinical phenomenon is mediated by the dopamine-blocking action of typical antipsychotic medications, which results in excessive prolactin secretion and secondary effects on gonadal function. This antipsychotic-induced sexual dysfunction is unacceptable to patients and is associated with nonadherence to medication, impacting on the overall clinical outcome and treatment success. Development of first-line atypical antipsychotic agents that do not affect prolactin production is therefore an important advance for patients requiring long-term antipsychotic therapy.
| Original language | English |
|---|---|
| Pages (from-to) | S27 - S32 |
| Journal | Journal of Clinical Psychopharmacology |
| Volume | 23 |
| Issue number | 3 |
| Publication status | Published - Jun 2003 |
| Event | International Meeting on Improvement Without Impairment in Psychotic and Mood Disorders - MONTREUX, Switzerland Duration: 1 Jan 2003 → … |
